Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Expression of concern Open Access | 10.1172/JCI213290

Expression of Concern for Chronic stress–induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis

Yongkang Wu, Yankun Zhang, Xiaojia Shi, Mengting Wu, Min Sun, Ying Feng, Wenmeng Ma, Xiule Jiang, Dingqi Fei, Mingjian Zhao, Zhuanchang Wu, Chunyang Li, Xiaohong Liang, Lifen Gao, Chunhong Ma, and Xuetian Yue

Find articles by Wu, Y. in: PubMed | Google Scholar

Find articles by Zhang, Y. in: PubMed | Google Scholar

Find articles by Shi, X. in: PubMed | Google Scholar

Find articles by Wu, M. in: PubMed | Google Scholar

Find articles by Sun, M. in: PubMed | Google Scholar

Find articles by Feng, Y. in: PubMed | Google Scholar

Find articles by Ma, W. in: PubMed | Google Scholar

Find articles by Jiang, X. in: PubMed | Google Scholar

Find articles by Fei, D. in: PubMed | Google Scholar

Find articles by Zhao, M. in: PubMed | Google Scholar

Find articles by Wu, Z. in: PubMed | Google Scholar |

Find articles by Li, C. in: PubMed | Google Scholar |

Find articles by Liang, X. in: PubMed | Google Scholar |

Find articles by Gao, L. in: PubMed | Google Scholar |

Find articles by Ma, C. in: PubMed | Google Scholar

Find articles by Yue, X. in: PubMed | Google Scholar |

Published October 1, 2026 - More info

Published in Volume 136, Issue 19 on October 1, 2026
J Clin Invest. 2026;136(19):e213290. https://doi.org/10.1172/JCI213290.
© 2026 Wu et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published October 1, 2026 - Version history
View PDF

Related article:

Chronic stress–induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis
Yongkang Wu, Yankun Zhang, Xiaojia Shi, Mengting Wu, Min Sun, Ying Feng, Wenmeng Ma, Xiule Jiang, Dingqi Fei, Mingjian Zhao, Zhuanchang Wu, Chunyang Li, Xiaohong Liang, Lifen Gao, Chunhong Ma, Xuetian Yue
Yongkang Wu, Yankun Zhang, Xiaojia Shi, Mengting Wu, Min Sun, Ying Feng, Wenmeng Ma, Xiule Jiang, Dingqi Fei, Mingjian Zhao, Zhuanchang Wu, Chunyang Li, Xiaohong Liang, Lifen Gao, Chunhong Ma, Xuetian Yue
Wu et al showed that chronic stress promotes APN expression to increase GSH synthesis and inhibit ferroptosis in liver cancer.
Research Article Cell biology Gastroenterology Hepatology

Chronic stress–induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis

  • Text
  • PDF
Abstract

Emerging evidence demonstrates that chronic stress alters immunological, neurochemical, and endocrinological functions, thereby promoting tumor progression. However, the underlying metabolic mechanism of chronic stress in tumor progression is still elusive. Using multiomics analysis, we found that aminopeptidase N (ANPEP) was upregulated in tumors with chronic restraint, associating with the reprogramming of amino acid metabolism. Functional assays revealed that ANPEP promoted liver cancer growth and metastasis. Knockdown of ANPEP blocked chronic stress–induced liver cancer progression. Chronic stress–induced glucocorticoids promoted nuclear receptor subfamily 3 group C member 1 nuclear translocation to activate ANPEP transcription by directly binding to its promoter. Furthermore, ANPEP promotes glutathione synthesis, subsequently inhibiting ROS-induced ferroptosis. Mechanistically, ANPEP interacted with solute carrier family 3 member 2 (SLC3A2) to block membrane associated ring-CH-type finger 8–mediated lysosome-dependent degradation of SLC3A2, promoting intracellular l-cystine transport, thereby increasing glutathione synthesis. The combination of ANPEP silencing and sorafenib treatment showed a synergistic effect in inhibiting liver cancer progression. Finally, clinical data and mouse models demonstrated that chronic stress drove liver tumor progression via ANPEP-regulated SLC3A2. These findings reveal unanticipated communication between chronic stress and metabolic reprogramming during liver cancer progression, providing potential therapeutic implications for liver cancer.

Authors

Yongkang Wu, Yankun Zhang, Xiaojia Shi, Mengting Wu, Min Sun, Ying Feng, Wenmeng Ma, Xiule Jiang, Dingqi Fei, Mingjian Zhao, Zhuanchang Wu, Chunyang Li, Xiaohong Liang, Lifen Gao, Chunhong Ma, Xuetian Yue

×

Original citation: J Clin Invest. 2026;136(4):e195685. https://doi.org/10.1172/JCI195685

Citation for this expression of concern: J Clin Invest. 2026;136(19):e213290. https://doi.org/10.1172/JCI213290

The authors recently alerted the Editors to errors pertaining to figures, supporting data values, and/or analysis of Figures 4I and 9K and Supplemental Figures 2H, 2I, 4H, and 5M that were identified in response to an institutional mandate for a post-publication audit of the data. Although the authors have indicated that the errors were due to inadvertent mistakes, the Editors are issuing this Expression of Concern to alert readers to the issues. We have requested institutional oversight into this matter and will alert readers to the outcome when the institutional evaluation is complete.

Footnotes

See the related article at Chronic stress–induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis.

Version history
  • Version 1 (October 1, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts